Free shipping on all orders over $ 500

Samotolisib

Cat. No. M8925

All AbMole products are for research use only, cannot be used for human consumption.

Samotolisib Structure
Synonym:

LY3023414

Size Price Availability Quantity
2mg USD 60  USD60 In stock
5mg USD 90  USD90 In stock
10mg USD 160  USD160 In stock
25mg USD 300  USD300 In stock
50mg USD 480  USD480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively.

In vitro, inhibition of PI3K/AKT/mTOR signaling by Samotolisib (LY3023414) causes G1 cell-cycle arrest and resulted in broad antiproliferative activity in cancer cell panel screens. In cell-based assays, LY3023414 inhibition of PI3K and mTOR is assessed in the PTEN-deficient U87 MG glioblastoma cell line. LY3023414 inhibits the phosphorylation of AKT at position T308 downstream of PI3K at an IC50 of 106 nM.

In vivo, LY3023414 (3, 6, or 10 mg/kg) twice daily orally for 28 days results in dose-responsive inhibition of tumor growth in the PTEN-deleted U87 MG xenograft model. This treatment produces similar TGI in models exhibiting PTEN truncation (786-O), activating PI3Kα mutation (NCI-H1975), and transgenic Eμ-myc mutant PI3Kα-driven leukemia models. Of note, the total daily dose of LY3023414 appears to result in equipotent antitumor activity: 12 mg/kg once daily and 6 mg/kg twice daily produces similar delta T/C values (42% and 38%, respectively) in U87 MG.

Customer Product Validations & Biological Datas
Source Oncotarget (2016 Nov). Figure 5. LY3023414
Method RNA-Seq analysis
Cell Lines BLCAb001 and BLCAb002 derived cells
Concentrations 0, 15, 120 nM
Incubation Time
Results Our RNAseq data showed BNIP3 and BCL11A upregulation, and ULK2, BAG1, RAB11FIP4 and BCLL14 downregulation in BLCAb001 tumors, mirroring the higher levels of LC3B I/II by Western blot analysis (Figure 5A and 5B).
Protocol (for reference only)
Cell Experiment
Cell lines RKO and SK-OV-3 cells; MOLT-4 and L-363 cells; DLD-1, HCT-116, HCT-15, and NCI-H460 cells
Preparation method The CellTiter-Glo luminescent cell viability assay system is used to measure the antiproliferative effects of LY3023414 after 2 cell doublings on cells plated on plastic or incubated for 2 weeks in soft agar with a collection of standard cell lines and human patient–derived tumor xenografts passaged in nude mice. For the soft-agar assay, RKO and SK-OV-3 cells; MOLT-4 and L-363 cells; DLD-1, HCT-116, HCT-15, and NCI-H460 cells are used. These standard cell lines are genotyped by STR and matched to existing STR reference genotypes. Oncotest PDX models (including model MX1 originally derived at NCI) are characterized using the Affymetrix genome-wide human SNP Array 6.0 as well as whole-exome sequencing. Genetic identity analysis confirm that all PDX models are derived from independent patient samples. Combination studies are conducted in which LY3023414 is mixed with other therapeutic agents in fixed ratios of concentrations corresponding to the IC50 equivalents of each single agent. The combination index at 50% inhibition (CI50) is calculated.
Concentrations
Incubation time
Animal Experiment
Animal models athymic nude, CD-1 nude and NMRI athymic nude mice(Xenograft tumors)
Formulation 1% HEC in distilled water containing 0.25% polysorbate 80 and 0.05% Dow-Corning Antifoam 1510-US
Dosages
Administration p.o.
Chemical Information
Molecular Weight 406.48
Formula C23H26N4O3
CAS Number 1386874-06-1
Solubility (25°C) DMSO: 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Wei L, et al. Oncotarget. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

[2] Smith MC, et al. Mol Cancer Ther. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.

Related PI3K Products
T-00127-HEV1

T-00127-HEV1 is a phosphatidylinositol 4-kinase III beta (PI4KB) inhibitor with an IC50 of 60 nM.

PI3Kγ inhibitor AZ2 

PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3).

NIBR-17 

NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.

RV-1729 

RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ).

Vulolisib 

Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Samotolisib, LY3023414 supplier, PI3K, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.